Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-520"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-21"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance of medicinal products (amendment of Regulation (EC) No 726/2004) - Pharmacovigilance (amendment of Directive 2001/83/EC) (debate)2
dcterms:Language	"fi"^^xsd:language2
lpv:document identification number	"en.20100921.18.2-520"2
lpv:hasSubsequent	lp_eu:2010-09-21-Speech-2-5212
lpv:speaker	lp:Anneli Jäätteenmäki2
lpv:spokenAs	unknown; Suomen Keskusta (2009-07-14--2014-06-30)3 member; AFET (2009-07-16--2012-01-18)3 substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (2009-09-16--2014-06-30)3 substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2013-04-13)3 member; Delegation for relations with the United States (2009-09-16--2014-06-30)3 substitute; AFCO (2009-07-16--2012-01-18)3 vice-chair; ALDE (2009-07-14--2012-01-26)3 substitute; SEDE (2009-07-16--2012-01-18)3
lpv:translated text	"The World Health Organisation has estimated that counterfeit medicines account for as much as 10% of the world’s pharmaceutical market. Counterfeit medicines are a matter of people’s health and welfare, and so the issue is a worrying one. It is a welcome move that improvements are now being made to patients’ access to information about medicines and their adverse reactions. In future, the information will be more easily accessible, for example, on new national and European websites dedicated to drug safety. Finally, I want to state my support for the rapporteur’s proposal that the Commission should be requested to produce a report on the environmental impact of medicines and assess whether there is a need to make further amendments to EU legislation on drugs in the near future. Thank you."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph